WO2008078109A3 - Medicament - Google Patents
Medicament Download PDFInfo
- Publication number
- WO2008078109A3 WO2008078109A3 PCT/GB2007/005010 GB2007005010W WO2008078109A3 WO 2008078109 A3 WO2008078109 A3 WO 2008078109A3 GB 2007005010 W GB2007005010 W GB 2007005010W WO 2008078109 A3 WO2008078109 A3 WO 2008078109A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agelastatin
- medicament
- metastasis
- modulators
- analogue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
There is disclosed the use of (-)-Agelastatin and / or an agelastatin analogue in the treatment of metastatic disease, pharmaceutical compositions comprising Agelastatin and other active agents, for example chemotherapeutic agents and an assay for the identification of modulators of metastasis and / or invasive cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0625783.6 | 2006-12-22 | ||
GBGB0625783.6A GB0625783D0 (en) | 2006-12-22 | 2006-12-22 | Medicament |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008078109A2 WO2008078109A2 (en) | 2008-07-03 |
WO2008078109A3 true WO2008078109A3 (en) | 2009-09-11 |
Family
ID=37758951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2007/005010 WO2008078109A2 (en) | 2006-12-22 | 2007-12-24 | Medicament |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0625783D0 (en) |
WO (1) | WO2008078109A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
WO2015042239A1 (en) | 2013-09-19 | 2015-03-26 | Massachusetts Institute Of Technology | Compounds, compositions and methods of agelastatin alkaloids |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
JP2024518543A (en) * | 2021-05-11 | 2024-05-01 | ベイラー ユニバーシティ | Agelastatin A Derivatives and Related Methods |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004106343A2 (en) * | 2003-05-30 | 2004-12-09 | Ufc Limited | Agelastatin derivatives of antitumour and gsk-3beta-inhibiting alkaloids |
WO2006055578A2 (en) * | 2004-11-16 | 2006-05-26 | Temple University - Of The Commonwealth Systems Of Higher Education | Asymmetric synthesis of (-)-agelastatin a |
-
2006
- 2006-12-22 GB GBGB0625783.6A patent/GB0625783D0/en not_active Ceased
-
2007
- 2007-12-24 WO PCT/GB2007/005010 patent/WO2008078109A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004106343A2 (en) * | 2003-05-30 | 2004-12-09 | Ufc Limited | Agelastatin derivatives of antitumour and gsk-3beta-inhibiting alkaloids |
WO2006055578A2 (en) * | 2004-11-16 | 2006-05-26 | Temple University - Of The Commonwealth Systems Of Higher Education | Asymmetric synthesis of (-)-agelastatin a |
Non-Patent Citations (2)
Title |
---|
FURGER K A ET AL: "THE FUNCTIONAL AND CLINICAL ROLES OF OSTEOPONTIN IN CANCER AND METASTASIS", CURRENT MOLECULAR MEDICINE, BENTHAM SCIENCE PUBLISHERS, vol. 1, no. 5, 1 January 2001 (2001-01-01), pages 621 - 632, XP008055151, ISSN: 1566-5240 * |
HALE KARL J ET AL: "Chemical biology and mechanism of action studies on the antitumour agent, (-)-Agelastatin A.", ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, vol. 228, no. Part 1, August 2004 (2004-08-01), & MEETING OF THE DIVISION OF CHEMICAL TOXICOLOGY OF THE AMERICAN-CHEMICAL-SOCIETY HELD AT THE 228TH N; PHILADELPHIA, PA, USA; AUGUST 22 -26, 2004, pages U909, XP009112708, ISSN: 0065-7727 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008078109A2 (en) | 2008-07-03 |
GB0625783D0 (en) | 2007-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008078109A3 (en) | Medicament | |
WO2008028965A3 (en) | Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof | |
WO2007146426A3 (en) | Nanoshells for drug delivery | |
WO2008017867A3 (en) | Antiretroviral solid oral composition with at least one water insoluble polymer | |
IL228952A0 (en) | Pharmaceutical compositions comprising ferric citrate for reducing serum phosphate levels, and use thereof for the preparation of medicaments for treating or ameliorating calcium-associated disorders | |
WO2007076423A3 (en) | INHIBITORS OF Akt ACTIVITY | |
WO2008039218A3 (en) | Inhibitors of bruton's tyrosine kinase | |
WO2009049184A9 (en) | Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors | |
WO2006013441A3 (en) | Use of probiotic bacteria for the preparation of topical compositions for skin protection | |
WO2008141308A3 (en) | Gene expression and pain | |
WO2005118601A3 (en) | Sulfonylethyl phosphorodiamidates for use in the treatment of cancer | |
CL2007002261A1 (en) | COMPOUNDS DERIVED FROM IMIDAZO [1,2-B] PIRIDAZINA, QUINASA INHIBITORS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OR PREVENTION OF CANCER. | |
EP1859793A4 (en) | Novel combinational use of sulfonamide compound | |
WO2006015263A3 (en) | Lonidamine analogs | |
ECSP077238A (en) | COMPOSITIONS FOR DELIVERY OF HIGHLY SOLUBLE DRUGS IN WATER | |
BRPI0513455A (en) | flavor masking formulation comprising the drug in a delayed dissolution form and / or cyclodextrin in an improved dissolution form | |
BRPI0815577A2 (en) | FOXM1 PEPTIDE AND MEDICAL AGENT UNDERSTANDING THE SAME. | |
WO2007064945A3 (en) | Cancer therapies and pharmaceutical compositions used therein | |
WO2004041269A3 (en) | New use for pharmaceutical composition | |
FR2886851B1 (en) | COMPOSITION BASED ON AVERMECTIN AND METRONIDAZOLE, IN PARTICULAR FOR THE TREATMENT OF ROSACEA | |
WO2008076954A3 (en) | Heterocycle compounds and methods of use thereof | |
WO2006133707A3 (en) | Anti-cancer combination treatment and kit-of-part | |
WO2005074925A8 (en) | Compositions substantially free of galactomannan containing piperacillin and tazobactam | |
WO2007059341A3 (en) | Pyrazolothiazole protein kinase modulators | |
WO2008054808A3 (en) | Elvucitabine pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07858809 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07858809 Country of ref document: EP Kind code of ref document: A2 |